Skip to main content
PMC home page
Philosophical Transactions of the Royal Society B: Biological Sciences logoLink to Philosophical Transactions of the Royal Society B: Biological Sciences
. 1999 Oct 29;354(1390):1697–1710. doi: 10.1098/rstb.1999.0513

Therapeutic strategies in multiple sclerosis. I. Immunotherapy.

R Hohlfeld 1
PMCID: PMC1692674  PMID: 10603621

Abstract

This review first addresses several general aspects of the immunotherapy of multiple sclerosis. Next, two approved immunomodulatory treatments, interferon-beta and copolymer-1 (glatiramer acetate), are reviewed in more detail. Finally, other immunosuppressive therapies and experimental strategies are briefly discussed.

Full Text

The Full Text of this article is available as a PDF (605.9 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aharoni R., Teitelbaum D., Arnon R., Sela M. Copolymer 1 acts against the immunodominant epitope 82-100 of myelin basic protein by T cell receptor antagonism in addition to major histocompatibility complex blocking. Proc Natl Acad Sci U S A. 1999 Jan 19;96(2):634–639. doi: 10.1073/pnas.96.2.634. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Aharoni R., Teitelbaum D., Sela M., Arnon R. Bystander suppression of experimental autoimmune encephalomyelitis by T cell lines and clones of the Th2 type induced by copolymer 1. J Neuroimmunol. 1998 Nov 2;91(1-2):135–146. doi: 10.1016/s0165-5728(98)00166-0. [DOI] [PubMed] [Google Scholar]
  3. Arnon R., Sela M., Teitelbaum D. New insights into the mechanism of action of copolymer 1 in experimental allergic encephalomyelitis and multiple sclerosis. J Neurol. 1996 Apr;243(4 Suppl 1):S8–13. doi: 10.1007/BF00873696. [DOI] [PubMed] [Google Scholar]
  4. Ben-Nun A., Mendel I., Bakimer R., Fridkis-Hareli M., Teitelbaum D., Arnon R., Sela M., Kerlero de Rosbo N. The autoimmune reactivity to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis is potentially pathogenic: effect of copolymer 1 on MOG-induced disease. J Neurol. 1996 Apr;243(4 Suppl 1):S14–S22. doi: 10.1007/BF00873697. [DOI] [PubMed] [Google Scholar]
  5. Bendtzen K., Hansen M. B., Ross C., Poulsen L. K., Svenson M. Cytokines and autoantibodies to cytokines. Stem Cells. 1995 May;13(3):206–222. doi: 10.1002/stem.5530130303. [DOI] [PubMed] [Google Scholar]
  6. Bornstein M. B., Miller A., Slagle S., Weitzman M., Crystal H., Drexler E., Keilson M., Merriam A., Wassertheil-Smoller S., Spada V. A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. N Engl J Med. 1987 Aug 13;317(7):408–414. doi: 10.1056/NEJM198708133170703. [DOI] [PubMed] [Google Scholar]
  7. Bornstein M. B., Miller A., Slagle S., Weitzman M., Drexler E., Keilson M., Spada V., Weiss W., Appel S., Rolak L. A placebo-controlled, double-blind, randomized, two-center, pilot trial of Cop 1 in chronic progressive multiple sclerosis. Neurology. 1991 Apr;41(4):533–539. doi: 10.1212/wnl.41.4.533. [DOI] [PubMed] [Google Scholar]
  8. Boutros T., Croze E., Yong V. W. Interferon-beta is a potent promoter of nerve growth factor production by astrocytes. J Neurochem. 1997 Sep;69(3):939–946. doi: 10.1046/j.1471-4159.1997.69030939.x. [DOI] [PubMed] [Google Scholar]
  9. Briscoe J., Kohlhuber F., Müller M. JAKs and STATs branch out. Trends Cell Biol. 1996 Sep;6(9):336–340. doi: 10.1016/0962-8924(96)10028-3. [DOI] [PubMed] [Google Scholar]
  10. Brod S. A., Marshall G. D., Jr, Henninger E. M., Sriram S., Khan M., Wolinsky J. S. Interferon-beta 1b treatment decreases tumor necrosis factor-alpha and increases interleukin-6 production in multiple sclerosis. Neurology. 1996 Jun;46(6):1633–1638. doi: 10.1212/wnl.46.6.1633. [DOI] [PubMed] [Google Scholar]
  11. Calabresi P. A., Pelfrey C. M., Tranquill L. R., Maloni H., McFarland H. F. VLA-4 expression on peripheral blood lymphocytes is downregulated after treatment of multiple sclerosis with interferon beta. Neurology. 1997 Oct;49(4):1111–1116. doi: 10.1212/wnl.49.4.1111. [DOI] [PubMed] [Google Scholar]
  12. Calabresi P. A., Tranquill L. R., Dambrosia J. M., Stone L. A., Maloni H., Bash C. N., Frank J. A., McFarland H. F. Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon beta-1b. Ann Neurol. 1997 May;41(5):669–674. doi: 10.1002/ana.410410517. [DOI] [PubMed] [Google Scholar]
  13. Chabot S., Williams G., Yong V. W. Microglial production of TNF-alpha is induced by activated T lymphocytes. Involvement of VLA-4 and inhibition by interferonbeta-1b. J Clin Invest. 1997 Aug 1;100(3):604–612. doi: 10.1172/JCI119571. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Darnell J. E., Jr, Kerr I. M., Stark G. R. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science. 1994 Jun 3;264(5164):1415–1421. doi: 10.1126/science.8197455. [DOI] [PubMed] [Google Scholar]
  15. Dayal A. S., Jensen M. A., Lledo A., Arnason B. G. Interferon-gamma-secreting cells in multiple sclerosis patients treated with interferon beta-1b. Neurology. 1995 Dec;45(12):2173–2177. doi: 10.1212/wnl.45.12.2173. [DOI] [PubMed] [Google Scholar]
  16. Durelli L., Bongioanni M. R., Cavallo R., Ferrero B., Ferri R., Ferrio M. F., Bradac G. B., Riva A., Vai S., Geuna M. Chronic systemic high-dose recombinant interferon alfa-2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte interferon gamma production in relapsing-remitting multiple sclerosis. Neurology. 1994 Mar;44(3 Pt 1):406–413. doi: 10.1212/wnl.44.3_part_1.406. [DOI] [PubMed] [Google Scholar]
  17. Fierlbeck G., Schreiner T., Schaber B., Walser A., Rassner G. Neutralizing interferon beta antibodies in melanoma patients treated with recombinant and natural interferon beta. Cancer Immunol Immunother. 1994 Oct;39(4):263–268. doi: 10.1007/BF01525990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Fridkis-Hareli M., Strominger J. L. Promiscuous binding of synthetic copolymer 1 to purified HLA-DR molecules. J Immunol. 1998 May 1;160(9):4386–4397. [PubMed] [Google Scholar]
  19. Genain C. P., Abel K., Belmar N., Villinger F., Rosenberg D. P., Linington C., Raine C. S., Hauser S. L. Late complications of immune deviation therapy in a nonhuman primate. Science. 1996 Dec 20;274(5295):2054–2057. doi: 10.1126/science.274.5295.2054. [DOI] [PubMed] [Google Scholar]
  20. Genain C. P., Cannella B., Hauser S. L., Raine C. S. Identification of autoantibodies associated with myelin damage in multiple sclerosis. Nat Med. 1999 Feb;5(2):170–175. doi: 10.1038/5532. [DOI] [PubMed] [Google Scholar]
  21. Genain C. P., Nguyen M. H., Letvin N. L., Pearl R., Davis R. L., Adelman M., Lees M. B., Linington C., Hauser S. L. Antibody facilitation of multiple sclerosis-like lesions in a nonhuman primate. J Clin Invest. 1995 Dec;96(6):2966–2974. doi: 10.1172/JCI118368. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Genç K., Dona D. L., Reder A. T. Increased CD80(+) B cells in active multiple sclerosis and reversal by interferon beta-1b therapy. J Clin Invest. 1997 Jun 1;99(11):2664–2671. doi: 10.1172/JCI119455. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Guthikonda P., Baker J., Mattson D. H. Interferon-beta-1-b (IFN-B) decreases induced nitric oxide (NO) production by a human astrocytoma cell line. J Neuroimmunol. 1998 Mar 1;82(2):133–139. doi: 10.1016/s0165-5728(97)00172-0. [DOI] [PubMed] [Google Scholar]
  24. Hall G. L., Compston A., Scolding N. J. Beta-interferon and multiple sclerosis. Trends Neurosci. 1997 Feb;20(2):63–67. doi: 10.1016/s0166-2236(96)10071-0. [DOI] [PubMed] [Google Scholar]
  25. Hofer M., Pagliusi S. R., Hohn A., Leibrock J., Barde Y. A. Regional distribution of brain-derived neurotrophic factor mRNA in the adult mouse brain. EMBO J. 1990 Aug;9(8):2459–2464. doi: 10.1002/j.1460-2075.1990.tb07423.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. Hohlfeld R. Biotechnological agents for the immunotherapy of multiple sclerosis. Principles, problems and perspectives. Brain. 1997 May;120(Pt 5):865–916. doi: 10.1093/brain/120.5.865. [DOI] [PubMed] [Google Scholar]
  27. Hohlfeld R. Neurological autoimmune disease and the trimolecular complex of T-lymphocytes. Ann Neurol. 1989 Jun;25(6):531–538. doi: 10.1002/ana.410250602. [DOI] [PubMed] [Google Scholar]
  28. Jacobs L. D., Cookfair D. L., Rudick R. A., Herndon R. M., Richert J. R., Salazar A. M., Fischer J. S., Goodkin D. E., Granger C. V., Simon J. H. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG) Ann Neurol. 1996 Mar;39(3):285–294. doi: 10.1002/ana.410390304. [DOI] [PubMed] [Google Scholar]
  29. Jacobs L., Johnson K. P. A brief history of the use of interferons as treatment of multiple sclerosis. Arch Neurol. 1994 Dec;51(12):1245–1252. doi: 10.1001/archneur.1994.00540240089022. [DOI] [PubMed] [Google Scholar]
  30. Johnson K. P., Brooks B. R., Cohen J. A., Ford C. C., Goldstein J., Lisak R. P., Myers L. W., Panitch H. S., Rose J. W., Schiffer R. B. Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group. Neurology. 1998 Mar;50(3):701–708. doi: 10.1212/wnl.50.3.701. [DOI] [PubMed] [Google Scholar]
  31. Kappos L., Moeri D., Radue E. W., Schoetzau A., Schweikert K., Barkhof F., Miller D., Guttmann C. R., Weiner H. L., Gasperini C. Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group. Lancet. 1999 Mar 20;353(9157):964–969. doi: 10.1016/s0140-6736(98)03053-0. [DOI] [PubMed] [Google Scholar]
  32. Karni A., Bakimer-Kleiner R., Abramsky O., Ben-Nun A. Elevated levels of antibody to myelin oligodendrocyte glycoprotein is not specific for patients with multiple sclerosis. Arch Neurol. 1999 Mar;56(3):311–315. doi: 10.1001/archneur.56.3.311. [DOI] [PubMed] [Google Scholar]
  33. Kerschensteiner M., Gallmeier E., Behrens L., Leal V. V., Misgeld T., Klinkert W. E., Kolbeck R., Hoppe E., Oropeza-Wekerle R. L., Bartke I. Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation? J Exp Med. 1999 Mar 1;189(5):865–870. doi: 10.1084/jem.189.5.865. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Khan O. A., Dhib-Jalbut S. S. Neutralizing antibodies to interferon beta-1a and interferon beta-1b in MS patients are cross-reactive. Neurology. 1998 Dec;51(6):1698–1702. doi: 10.1212/wnl.51.6.1698. [DOI] [PubMed] [Google Scholar]
  35. Kojima K., Berger T., Lassmann H., Hinze-Selch D., Zhang Y., Gehrmann J., Reske K., Wekerle H., Linington C. Experimental autoimmune panencephalitis and uveoretinitis transferred to the Lewis rat by T lymphocytes specific for the S100 beta molecule, a calcium binding protein of astroglia. J Exp Med. 1994 Sep 1;180(3):817–829. doi: 10.1084/jem.180.3.817. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Lassmann H., Raine C. S., Antel J., Prineas J. W. Immunopathology of multiple sclerosis: report on an international meeting held at the Institute of Neurology of the University of Vienna. J Neuroimmunol. 1998 Jun 15;86(2):213–217. doi: 10.1016/s0165-5728(98)00031-9. [DOI] [PubMed] [Google Scholar]
  37. Leppert D., Waubant E., Bürk M. R., Oksenberg J. R., Hauser S. L. Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann Neurol. 1996 Dec;40(6):846–852. doi: 10.1002/ana.410400606. [DOI] [PubMed] [Google Scholar]
  38. Lewin G. R., Barde Y. A. Physiology of the neurotrophins. Annu Rev Neurosci. 1996;19:289–317. doi: 10.1146/annurev.ne.19.030196.001445. [DOI] [PubMed] [Google Scholar]
  39. Linington C., Berger T., Perry L., Weerth S., Hinze-Selch D., Zhang Y., Lu H. C., Lassmann H., Wekerle H. T cells specific for the myelin oligodendrocyte glycoprotein mediate an unusual autoimmune inflammatory response in the central nervous system. Eur J Immunol. 1993 Jun;23(6):1364–1372. doi: 10.1002/eji.1830230627. [DOI] [PubMed] [Google Scholar]
  40. Linington C., Bradl M., Lassmann H., Brunner C., Vass K. Augmentation of demyelination in rat acute allergic encephalomyelitis by circulating mouse monoclonal antibodies directed against a myelin/oligodendrocyte glycoprotein. Am J Pathol. 1988 Mar;130(3):443–454. [PMC free article] [PubMed] [Google Scholar]
  41. Lu H. T., Riley J. L., Babcock G. T., Huston M., Stark G. R., Boss J. M., Ransohoff R. M. Interferon (IFN) beta acts downstream of IFN-gamma-induced class II transactivator messenger RNA accumulation to block major histocompatibility complex class II gene expression and requires the 48-kD DNA-binding protein, ISGF3-gamma. J Exp Med. 1995 Nov 1;182(5):1517–1525. doi: 10.1084/jem.182.5.1517. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Lucchinetti C. F., Brück W., Rodriguez M., Lassmann H. Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis. Brain Pathol. 1996 Jul;6(3):259–274. doi: 10.1111/j.1750-3639.1996.tb00854.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Malik O., Compston D. A., Scolding N. J. Interferon-beta inhibits mitogen induced astrocyte proliferation in vitro. J Neuroimmunol. 1998 Jun 15;86(2):155–162. doi: 10.1016/s0165-5728(98)00049-6. [DOI] [PubMed] [Google Scholar]
  44. Martínez-Cáceres E. M., Río J., Barrau M., Durán I., Borrás C., Tintoré M., Montalban X. Amelioration of flulike symptoms at the onset of interferon beta-1b therapy in multiple sclerosis by low-dose oral steroids is related to a decrease in interleukin-6 induction. Ann Neurol. 1998 Oct;44(4):682–685. doi: 10.1002/ana.410440415. [DOI] [PubMed] [Google Scholar]
  45. McRae B. L., Semnani R. T., Hayes M. P., van Seventer G. A. Type I IFNs inhibit human dendritic cell IL-12 production and Th1 cell development. J Immunol. 1998 May 1;160(9):4298–4304. [PubMed] [Google Scholar]
  46. Miller A., Shapiro S., Gershtein R., Kinarty A., Rawashdeh H., Honigman S., Lahat N. Treatment of multiple sclerosis with copolymer-1 (Copaxone): implicating mechanisms of Th1 to Th2/Th3 immune-deviation. J Neuroimmunol. 1998 Dec 1;92(1-2):113–121. doi: 10.1016/s0165-5728(98)00191-x. [DOI] [PubMed] [Google Scholar]
  47. Moalem G., Leibowitz-Amit R., Yoles E., Mor F., Cohen I. R., Schwartz M. Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy. Nat Med. 1999 Jan;5(1):49–55. doi: 10.1038/4734. [DOI] [PubMed] [Google Scholar]
  48. Myhr K. M., Riise T., Green Lilleås F. E., Beiske T. G., Celius E. G., Edland A., Jensen D., Larsen J. P., Nilsen R., Nortvedt M. W. Interferon-alpha2a reduces MRI disease activity in relapsing-remitting multiple sclerosis. Norwegian Study Group on Interferon-alpha in Multiple Sclerosis. Neurology. 1999 Mar 23;52(5):1049–1056. doi: 10.1212/wnl.52.5.1049. [DOI] [PubMed] [Google Scholar]
  49. Neumann H., Wekerle H. Neuronal control of the immune response in the central nervous system: linking brain immunity to neurodegeneration. J Neuropathol Exp Neurol. 1998 Jan;57(1):1–9. doi: 10.1097/00005072-199801000-00001. [DOI] [PubMed] [Google Scholar]
  50. Noseworthy J. H., Gold R., Hartung H. P. Treatment of multiple sclerosis: recent trials and future perspectives. Curr Opin Neurol. 1999 Jun;12(3):279–293. doi: 10.1097/00019052-199906000-00007. [DOI] [PubMed] [Google Scholar]
  51. Panitch H. S., Hirsch R. L., Schindler J., Johnson K. P. Treatment of multiple sclerosis with gamma interferon: exacerbations associated with activation of the immune system. Neurology. 1987 Jul;37(7):1097–1102. doi: 10.1212/wnl.37.7.1097. [DOI] [PubMed] [Google Scholar]
  52. Paty D. W., Li D. K. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Neurology. 1993 Apr;43(4):662–667. doi: 10.1212/wnl.43.4.662. [DOI] [PubMed] [Google Scholar]
  53. Pette M., Pette D. F., Muraro P. A., Farnon E., Martin R., McFarland H. F. Interferon-beta interferes with the proliferation but not with the cytokine secretion of myelin basic protein-specific, T-helper type 1 lymphocytes. Neurology. 1997 Aug;49(2):385–392. doi: 10.1212/wnl.49.2.385. [DOI] [PubMed] [Google Scholar]
  54. Rep M. H., Hintzen R. Q., Polman C. H., van Lier R. A. Recombinant interferon-beta blocks proliferation but enhances interleukin-10 secretion by activated human T-cells. J Neuroimmunol. 1996 Jul;67(2):111–118. doi: 10.1016/0165-5728(96)00060-4. [DOI] [PubMed] [Google Scholar]
  55. Rudick R. A., Carpenter C. S., Cookfair D. L., Tuohy V. K., Ransohoff R. M. In vitro and in vivo inhibition of mitogen-driven T-cell activation by recombinant interferon beta. Neurology. 1993 Oct;43(10):2080–2087. doi: 10.1212/wnl.43.10.2080. [DOI] [PubMed] [Google Scholar]
  56. Rudick R. A., Ransohoff R. M., Lee J. C., Peppler R., Yu M., Mathisen P. M., Tuohy V. K. In vivo effects of interferon beta-1a on immunosuppressive cytokines in multiple sclerosis. Neurology. 1998 May;50(5):1294–1300. doi: 10.1212/wnl.50.5.1294. [DOI] [PubMed] [Google Scholar]
  57. Rudick R. A., Ransohoff R. M., Peppler R., VanderBrug Medendorp S., Lehmann P., Alam J. Interferon beta induces interleukin-10 expression: relevance to multiple sclerosis. Ann Neurol. 1996 Oct;40(4):618–627. doi: 10.1002/ana.410400412. [DOI] [PubMed] [Google Scholar]
  58. Rudick R. A., Simonian N. A., Alam J. A., Campion M., Scaramucci J. O., Jones W., Coats M. E., Goodkin D. E., Weinstock-Guttman B., Herndon R. M. Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG) Neurology. 1998 May;50(5):1266–1272. doi: 10.1212/wnl.50.5.1266. [DOI] [PubMed] [Google Scholar]
  59. Schmidt S., Hertfelder H. J., von Spiegel T., Hering R., Harzheim M., Lassmann H., Deckert-Schlüter M., Schlegel U. Lethal capillary leak syndrome after a single administration of interferon beta-1b. Neurology. 1999 Jul 13;53(1):220–222. doi: 10.1212/wnl.53.1.220. [DOI] [PubMed] [Google Scholar]
  60. Steinman L. Connections between the immune system and the nervous system. Proc Natl Acad Sci U S A. 1993 Sep 1;90(17):7912–7914. doi: 10.1073/pnas.90.17.7912. [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Stone L. A., Frank J. A., Albert P. S., Bash C., Smith M. E., Maloni H., McFarland H. F. The effect of interferon-beta on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsing-remitting multiple sclerosis. Ann Neurol. 1995 May;37(5):611–619. doi: 10.1002/ana.410370511. [DOI] [PubMed] [Google Scholar]
  62. Storch M. K., Stefferl A., Brehm U., Weissert R., Wallström E., Kerschensteiner M., Olsson T., Linington C., Lassmann H. Autoimmunity to myelin oligodendrocyte glycoprotein in rats mimics the spectrum of multiple sclerosis pathology. Brain Pathol. 1998 Oct;8(4):681–694. doi: 10.1111/j.1750-3639.1998.tb00194.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. Stüve O., Dooley N. P., Uhm J. H., Antel J. P., Francis G. S., Williams G., Yong V. W. Interferon beta-1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann Neurol. 1996 Dec;40(6):853–863. doi: 10.1002/ana.410400607. [DOI] [PubMed] [Google Scholar]
  64. Teitelbaum D., Fridkis-Hareli M., Arnon R., Sela M. Copolymer 1 inhibits chronic relapsing experimental allergic encephalomyelitis induced by proteolipid protein (PLP) peptides in mice and interferes with PLP-specific T cell responses. J Neuroimmunol. 1996 Feb;64(2):209–217. doi: 10.1016/0165-5728(95)00180-8. [DOI] [PubMed] [Google Scholar]
  65. Van Weyenbergh J., Lipinski P., Abadie A., Chabas D., Blank U., Liblau R., Wietzerbin J. Antagonistic action of IFN-beta and IFN-gamma on high affinity Fc gamma receptor expression in healthy controls and multiple sclerosis patients. J Immunol. 1998 Aug 1;161(3):1568–1574. [PubMed] [Google Scholar]
  66. Weber F., Janovskaja J., Polak T., Poser S., Rieckmann P. Effect of interferon beta on human myelin basic protein-specific T-cell lines: comparison of IFNbeta-1a and IFNbeta-1b. Neurology. 1999 Mar 23;52(5):1069–1071. doi: 10.1212/wnl.52.5.1069. [DOI] [PubMed] [Google Scholar]
  67. Weber F., Polak T., Günther A., Kubuschok B., Janovskaja J., Bitsch A., Poser S., Rieckmann P. Synergistic immunomodulatory effects of interferon-beta1b and the phosphodiesterase inhibitor pentoxifylline in patients with relapsing-remitting multiple sclerosis. Ann Neurol. 1998 Jul;44(1):27–34. doi: 10.1002/ana.410440109. [DOI] [PubMed] [Google Scholar]
  68. Weinstock-Guttman B., Ransohoff R. M., Kinkel R. P., Rudick R. A. The interferons: biological effects, mechanisms of action, and use in multiple sclerosis. Ann Neurol. 1995 Jan;37(1):7–15. doi: 10.1002/ana.410370105. [DOI] [PubMed] [Google Scholar]
  69. Wekerle H., Kojima K., Lannes-Vieira J., Lassmann H., Linington C. Animal models. Ann Neurol. 1994;36 (Suppl):S47–S53. doi: 10.1002/ana.410360714. [DOI] [PubMed] [Google Scholar]
  70. Wraith D. C., McDevitt H. O., Steinman L., Acha-Orbea H. T cell recognition as the target for immune intervention in autoimmune disease. Cell. 1989 Jun 2;57(5):709–715. doi: 10.1016/0092-8674(89)90786-1. [DOI] [PubMed] [Google Scholar]
  71. Yong V. W., Chabot S., Stuve O., Williams G. Interferon beta in the treatment of multiple sclerosis: mechanisms of action. Neurology. 1998 Sep;51(3):682–689. doi: 10.1212/wnl.51.3.682. [DOI] [PubMed] [Google Scholar]

Articles from Philosophical Transactions of the Royal Society B: Biological Sciences are provided here courtesy of The Royal Society

RESOURCES